China vs Mus: The number of people with susceptibility test result for rifampicin
China
237,238
in 2021
Mus
83
in 2021
China rank
2nd
Mus rank
1st
The number of people with susceptibility test result for rifampicin over time
- China
- Mus
How they compare
China currently reports 237,238 against 83 in Mus, a difference of 237,155.
That makes China's figure about 2,858.3 times Mus's.
Across all 5 years both countries report, China has been ahead every year.
China ranks 2nd and Mus ranks 1st of 155 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | China | Mus | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 156,421 | 111 | 156,310 | China |
| 2020s | 242,912 | 83 | 242,830 | China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, China or Mus?
- China, at 237,238 against 83 in Mus as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between China and Mus?
- 237,155, with China ahead.
- How many years of comparable data are there for China and Mus?
- 5 years are reported by both, from 2017 to 2021.
- How do China and Mus rank globally for the number of people with susceptibility test result for rifampicin?
- China ranks 2nd and Mus ranks 1st of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.